Certolizumab Offers Relief From Moderate-to-Severe Psoriasis


20 marzo 2017 - 12:25Rassegna stampa


Patients who received the targeted agent certolizumab for chronic moderate-to-severe plaque psoriasis achieved better outcomes than patients assigned to placebo -- even to the point of having nearly clear skin after 16 weeks of treatment, according to results from 2 similar phase 3 trials, reported at the 2017 Annual Meeting of the American Academy of Dermatology (AAD).

The primary endpoint of CIMPASI 1 was the percentage of patients who responded enough to therapy to achieve a Psoriasis Area and Severity Index 75% improvement (PASI-75) score, explained lead author Alice Gottlieb, MD, PhD, New York Medical College, Valhalla, New York, speaking here at an oral late-breaker session on March 4. This result was 6.5% among placebo subjects and 66.5% for patients on certolizumab 200 mg taken every 2 weeks and 75.8% of patients on certolizumab 400 mg administered every 2 weeks (P < .0001 vs placebo for both active arms).

In the CIMPASI 2 trial, 11.6% of people on placebo achieved a PASI-75 compared with 81.4% of patients on certolizumab 200 mg and 82.6% of patients on certolizumab 400 mg (P < .0001).

The results were similar when the researchers considered Physicians Global Assessment scores of 0/1. In CIMPASI 1, that goal was reached by 4.2% of subjects on placebo but 47.0% of patients on certolizumab 200 mg and 57.9% of patients on certolizumab 400 mg (P < .0001). In CIMPASI 2, two percent of placebo subjects reached the standard compared with 66.8% of patients on certolizumab 200 mg and 71.6% of patients on certolizumab 400 mg (P < .0001).

On the Dermatology Life Quality Index, after 16 weeks of therapy in CIMPASI 1, placebo subjects experienced a mean decline of 3.3 points compared with a 9.3-point reduction among patients on certolizumab 200 mg and a 10.2-point decline among patients on certolizumab 400 mg (P < .0001). In CIMPASI 2, placebo subjects achieved a 3.8-point decline compared with a 10.4-point decline among patients on certolizumab 200 mg and a 10.0-point decline among patients on certolizumab 400 mg (P < .0001).

In reviewing the adverse events in the study, Dr. Gottlieb said there were no new certolizumab-related concerns.

Funding for this study was provided by Dermira, Inc., Menlo Park, California.

[Presentation title: Certollzumab Pegol Treatment for Chronic Plaque Psoriasis: 16-Week Primary Results From two Phase 3, Multicenter, Randomized, Placebo-Controlled Studies. Abstract 5077]

Inserito da segreteria SIDeMaST

La rassegna stampa contiene articoli di interesse dermatologico tratti da testate nazionali e non intende fornire una revisione critica né essere una fonte di notizie scientificamente validate. Si accettano (e sono bene graditi) commenti da parte dei soci esperti nel settore.

Lascia un commento sul sito e rispondi all'autore

I commenti sono soggetti a moderazione: non saranno pubblicati immediatamente ma dovranno essere approvati dalla segreteria.

Eventi SIDeMaST

Stato iscrizione